SAVE TIME FOR THE THINGS YOU LOVE. ENROLL IN AUTO PAY TODAY.
Clinical & Payment Policies
Clinical Policies
Clinical policies are one set of guidelines used to assist in administering health plan benefits, either by prior authorization or payment rules. They include but are not limited to policies relating to evolving medical technologies and procedures, as well as pharmacy policies. Clinical policies help identify whether services are medically necessary based on information found in generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by the policy; and other available clinical information.
All policies found in the Ambetter of Alabama Clinical Policy Manual apply to Ambetter of Alabama members. Policies in the Ambetter of Alabama Clinical Policy Manual may have either a Ambetter of Alabama or a “Centene” heading. Ambetter of Alabama utilizes InterQual® criteria for those medical technologies, procedures or pharmaceutical treatments for which a Ambetter of Alabama clinical policy does not exist. InterQual is a nationally recognized evidence-based decision support tool. You may access the InterQual® SmartSheet(s)™ for Adult and Pediatric procedures, durable medical equipment and imaging procedures by logging into the secure provider portal or by calling Ambetter of Alabama. In addition, Ambetter of Alabama may from time to time delegate utilization management of specific services; in such circumstances, the delegated vendor’s guidelines may also be used to support medical necessity and other coverage determinations. Other non-clinical policies (e.g., payment policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Clinical Policy Manuals or InterQual®criteria is payable by Ambetter of Alabama.
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
- Acupuncture (CP.MP.92) (PDF)
- Adopted Clinical Practice and Preventive Health Guidelines (CPG Grid) (PDF)
- Air Ambulance (CP.MP.175) (PDF)
- Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-Thalassemia (CP.MP.108) (PDF)
- Applied Behavior Analysis (CP.BH.104) (PDF)
- Applied Behavioral Analysis Documentation Requirements (CP.BH.105) (PDF)
- Assisted Reproductive Technology (CP.MP.55) (PDF)
- Bariatric Surgery (CP.MP.37) (PDF)
- Behavioral Health Treatment Documentation Requirements (HIM.CP.BH.500) (PDF)
- Biofeedback (CP.MP.168) (PDF)
- Biofeedback for Behavioral Health Disorders (CP.BH.300) (PDF)
- Bone-Anchored Hearing Aid (CP.MP.93) (PDF)
- Burn Surgery (CP.MP.186) (PDF)
- Caudal or Interlaminar Epidural Steroid Injections (CP.MP.164) (PDF)
- Clinical Trials (CP.MP.94) (PDF)
- Cochlear Implant Replacements (CP.MP.14) (PDF)
- Concert Genetics Oncology: Algorithmic Testing (V1.2025) (PDF)
- Concert Genetics Oncology: Cancer Screening (V1.2025) (PDF)
- Concert Genetics Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy) (V1.2025) (PDF)
- Concert Genetics Oncology: Cytogenetic Testing (V1.2025) (PDF)
- Concert Genetics Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies (V1.2025) (PDF)
- Concert Genetic Testing: Aortopathies and Connective Tissue Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Cardiac Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Dermatologic Conditions (V1.2025) (PDF)
- Concert Genetic Testing: Epilepsy, Neurodegenerative, and Neuromuscular Conditions (V1.2025) (PDF)
- Concert Genetic Testing: Exome and Genome Sequencing for the Diagnosis of Genetic Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Eye Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Gastroenterologic Disorders (non cancerous) (V1.2025) (PDF)
- Concert Genetic Testing: General Approach to Genetic and Molecular Testing (V1.2025) (PDF)
- Concert Genetic Testing: Hearing Loss (V1.2025) (PDF)
- Concert Genetic Testing: Hematologic Conditions (non cancerous) (V1.2025) (PDF)
- Concert Genetic Testing: Hereditary Cancer Susceptibility (V1.2025) (PDF)
- Concert Genetic Testing: Immune, Autoimmune, and Rheumatoid Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Kidney Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Lung Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Metabolic, Endocrine, and Mitochondrial Disorders (V1.2025) (PDF)
- Concert Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay (V1.2025) (PDF)
- Concert Genetic Testing: Pharmacogenetics (Version B) (V1.2025) (PDF)
- Concert Genetic Testing: Preimplantation Genetic Testing (V1.2025) (PDF)
- Concert Genetic Testing: Prenatal and Preconception Carrier Screening (V1.2025) (PDF)
- Concert Genetic Testing: Prenatal Cell-Free DNA Testing (V1.2025) (PDF)
- Concert Genetic Testing: Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss (V1.2025) (PDF)
- Concert Genetic Testing: Skeletal Dysplasia and Rare Bone Disorders (V1.2025) (PDF)
- Cosmetic and Reconstructive Procedures (CP.MP.31) (PDF)
- Deep Transcranial Magnetic Stimulation for Obsessive Compulsive Disorder (CP.BH.201) (PDF)
- Diaphragmatic/Phrenic Nerve Stimulation (CP.MP.203) (PDF)
- Disc Decompression Procedures (CP.MP.114) (PDF)
- Discography (CP.MP.115) (PDF)
- Donor Lymphocyte Infusion (CP.MP.101) (PDF)
- Durable Medical Equipment and Orthotics and Prosthetics Guidelines (CP.MP.107) (PDF)
- Electric Tumor Treating Fields (Optune) (CP.MP.145) (PDF)
- Experimental Technologies (CP.MP.36) (PDF)
- Facet Joint Interventions (CP.MP.171) (PDF)
- Facility-based Sleep Studies for Obstructive Sleep Apnea (CP.MP.248) (PDF)
- Fecal Incontinence Treatments (CP.MP.137) (PDF)
- Fertility Preservation (CP.MP.130) (PDF)
- Fetal Surgery in Utero for Prenatally Diagnosed Malformations (CP.MP.129) (PDF)
- Gastric Electrical Stimulation (CP.MP.40) (PDF)
- Gender-Affirming Procedures (CP.MP.95) (PDF)
- Heart-Lung Transplant (CP.MP.132) (PDF)
- Home Births (CP.MP.136) (PDF)
- Home Ventilators (CP.MP.184) (PDF)
- Hospice Services (CP.MP.54) (PDF)
- Hyperhidrosis Treatments (CP.MP.62) (PDF)
- Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea (CP.MP.180) (PDF)
- Implantable Intrathecal Pain Pump (CP.MP.173) (PDF)
- Implantable Loop Recorder (CP.MP.243) (PDF)
- Implantable Wireless Pulmonary Artery Pressure Monitoring (CP.MP.160) (PDF)
- Intensity-Modulated Radiotherapy (CP.MP.69) (PDF)
- Intestinal and Multivisceral Transplant (CP.MP.58) (PDF)
- Intradiscal Steroid Injections for Pain Management (CP.MP.167) (PDF)
- IV Moderate Sedation, IV Deep Sedation, and General Anesthesia for Dental Procedures (CP.MP.61) (PDF)
- Lantidra (donislecel): Allogeneic Pancreatic Islet Cellular Therapy (CP.MP.250) (PDF)
- Liposuction for Lipedema (CP.MP.244) (PDF)
- Long Term Care Placement (CP.MP.71) (PDF)
- Lung Transplantation (CP.MP.57) (PDF)
- Lysis of Epidural Lesions (CP.MP.116) (PDF)
- Mechanical Stretching Devices for Joint Stiffness and Contracture (CP.MP.144) (PDF)
- Multiple Sleep Latency Testing (CP.MP.24) (PDF)
- Neonatal Abstinence Syndrome Guidelines (CP.MP.86) (PDF)
- Neonatal Sepsis Management (CP.MP.85) (PDF)
- Nerve Blocks and Neurolysis for Pain Management (CP.MP.170) (PDF)
- Neuromuscular and Peroneal Nerve Electrical Stimulation (NMES) (CP.MP.48) (PDF)
- NICU Apnea Bradycardia Guidelines (CP.MP.82) (PDF)
- NICU Discharge Guidelines (CP.MP.81) (PDF)
- Nonmyeloablative Allogeneic Stem Cell Transplants (CP.MP.141) (PDF)
- Obstetrical Home Care Programs (CP.MP.91) (PDF)
- Omisirge (omidubicel): Nicotinamide-modified Allogeneic Hematopoietic Progenitor Cell Therapy (CP.MP.249) (PDF)
- Orthognathic Surgery (CP.MP.202) (PDF)
- Osteogenic Stimulation (CP.MP.194) (PDF)
- Outpatient Cardiac Rehabilitation (CP.MP.176) (PDF)
- Outpatient Oxygen Use (CP.MP.190) (PDF)
- Pancreas Transplantation (CP.MP.102) (PDF)
- Panniculectomy (CP.MP.109) (PDF)
- Pediatric Heart Transplant (CP.MP.138) (PDF)
- Pediatric Kidney Transplant (CP.MP.246) (PDF)
- Pediatric Liver Transplant (CP.MP.120) (PDF)
- Pediatric Oral Function Therapy (CP.MP.188) (PDF)
- Percutaneous Left Atrial Appendage Closure Device for Stroke Prevention (CP.MP.147) (PDF)
- Phototherapy for Neonatal Hyperbilirubinemia (CP.MP.150) (PDF)
- Physical, Occupational, and Speech Therapy Services (CP.MP.49) (PDF)
- Posterior Tibial Nerve Stimulation for Voiding Dysfunction (CP.MP.133) (PDF)
- Proton and Neutron Beam Therapies (CP.MP.70) (PDF)
- Reduction Mammoplasty and Gynecomastia Surgery (CP.MP.51) (PDF)
- Repair of Nasal Valve Compromise (CP.MP.210) (PDF)
- Sacroiliac Joint Fusion (CP.MP.126) (PDF)
- Sacroiliac Joint Interventions for Pain Management (CP.MP.166) (PDF)
- Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins and Other Symptomatic Venous Disorders (CP.MP.146) (PDF)
- Selective Dorsal Rhizotomy for Spasticity in Cerebral Palsy (CP.MP.174) (PDF)
- Selective Nerve Root Blocks and Transforaminal Epidural Steroid Injections (CP.MP.165) (PDF)
- Short Inpatient Hospital Stay (CP.MP.182) (PDF)
- Skin and Soft Tissue Substitutes for Chronic Wounds (CP.MP.185) (PDF)
- Spinal Cord, Peripheral Nerve, and Percutaneous Electrical Nerve Stimulation (CP.MP.117) (PDF)
- Stereotactic Body Radiation Therapy (CP.MP.22) (PDF)
- Tandem Transplant (CP.MP.162) (PDF)
- Therapeutic Utilization of Inhaled Nitric Oxide (CP.MP.87) (PDF)
- Total Artificial Heart (CP.MP.127) (PDF)
- Total Parenteral Nutrition and Intradialytic Parenteral Nutrition (CP.MP.163) (PDF)
- Transcranial Magnetic Stimulation for Treatment Resistant Major Depression (CP.BH.200) (PDF)
- Transplant Service Documentation Requirements (CP.MP.247) (PDF)
- Trigger Point Injections for Pain Management (CP.MP.169) (PDF)
- Urinary Incontinence Devices and Treatments (CP.MP.142) (PDF)
- Vagus Nerve Stimulation (CP.MP.12) (PDF)
- Ventricular Assist Devices (CP.MP.46) (PDF)
Payment Policies
Health care claims payment policies are guidelines used to assist in administering payment rules based on generally accepted principles of correct coding. They are used to help identify whether health care services are correctly coded for reimbursement. Each payment rule is sourced by a generally accepted coding principle. They include, but are not limited to claims processing guidelines referenced by the Centers for Medicare and Medicaid Services (CMS), Publication 100-04, Claims Processing Manual for physicians/non-physician practitioners, the CMS National Correct Coding Initiative policy manual (procedure-to-procedure coding combination edits and medically unlikely edits), Current Procedural Technology guidance published by the American Medical Association (AMA) for reporting medical procedures and services, health plan clinical policies based on the appropriateness of health care and medical necessity, and at times state-specific claims reimbursement guidance.
All policies found in the Ambetter of Alabama Payment Policy Manual apply with respect to Ambetter of Alabama members. Policies in the Ambetter of Alabama Payment Policy Manual may have either a Ambetter of Alabama or a “Centene” heading. In addition, Ambetter of Alabama may from time to time employ a vendor that applies payment policies to specific services; in such circumstances, the vendor’s guidelines may also be used to determine whether a service has been correctly coded. Other policies (e.g., clinical policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Payment Policy Manual is payable by Ambetter of Alabama.
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
- 25-hydroxyvitamin D Testing in Children and Adolescents (CP.MP.157) (PDF)
- 3 Day Payment Window (PDF) Effective Date: 6/1/2023
- 30 Day Readmission (PDF) Effective Date: 1/1/2024
- Add on Code Billed Without Primary Code (PDF) Effective Date: 1/1/2013
- Allergy Testing and Therapy (CP.MP.100) (PDF)
- Assistant Surgeon (PDF) Effective Date: 1/1/2014
- Attention Deficit Hyperactivity Disorder Assessment and Treatment (CP.BH.124) (PDF)
- Bilateral Procedures (PDF) Effective Date: 1/1/2014
- Bronchial Thermoplasty (CP.MP.110) (PDF)
- Cardiac Biomarker Testing (CP.MP.156) (PDF)
- Coding Overview (PDF) Effective Date: 1/1/2013
- Cosmetic Procedures (PDF) Effective Date: 1/1/2014
- Digital EEG Spike Analysis (CP.MP.105) (PDF)
- Distinct Procedural Modifiers: XE, XS, XP, & XU (PDF) Effective Date: 1/1/2013
- Drugs of Abuse: Definitive Testing (CP.MP.50) (PDF)
- EEG in the Evaluation of Headache (PDF)
- E/M Bundling with Labs and Radiology (PDF) Effective Date: 1/1/2013
- E&M Services Billed with Treatment Room Revenue Codes (PDF) Effective Date: 1/1/23
- Endometrial Ablation (CP.MP.106) (PDF)
- Evaluation and Management Services Billed with Treatment Rooms (PDF) Effective Date: 6/1/2023
- Evoked Potential Testing ( CP.MP.134) (PDF)
- Extended Ophthalmoscopy (PDF)
- External Ocular Photography (PDF) Effective Date: 6/1/2023
- Fluorescein Angiography (PDF)
- Fundus Photography (PDF)
- Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing (CP.MP.209) (PDF)
- Gonioscopy (PDF)
- Helicobacter Pylori Serology Testing (CP.MP.153) (PDF)
- Holter Monitors (CP.MP.113) (PDF)
- Homocysteine Testing (CP.MP.121) (PDF)
- Inpatient Consultation (PDF) Effective Date: 1/1/2014
- Inpatient Only Procedures (PDF) Effective Date: 12/1/22
- Laser Therapy for Skin Conditions (CP.MP.123) (PDF)
- Low-Frequency Ultrasound and Noncontact Normothermic Wound Therapy (CP.MP.139) (PDF)
- Measurement of Serum 1,25-dihydroxyvitamin D (CP.MP.152) (PDF)
- Modifier DOS Validation (PDF) Effective Date: 1/1/2013
- Modifier to Procedure Code Validation (PDF) Effective Date: 1/1/2013
- Multiple CPT Codes Replacement (PDF) Effective Date: 1/1/2014
- Multiple Diagnostic Cardiovascular Procedure Payment Reduction (MDCR) (PDF) Effective Date: 6/1/2023
- Multiple Procedure Payment Reduction for Therapeutic Services (PDF) Effective Date: 6/1/2023
- Multiple Procedure Reduction: Ophthalmology (PDF) Effective Date: 6/1/2023
- NCCI Unbundling (PDF) Effective Date: 12/1/22
- New Patient (PDF) Effective Date: 1/1/2014
- Non-Obstetrical and OB Pelvic and Transvaginal Ultrasounds (PDF) Effective Date: 6/1/2023
- Outpatient Consultations (PDF) Effective Date: 1/1/2014
- Paclitaxel Protein Bound (PDF) Effective Date: 6/1/2023
- Physician's Consultation Services (PDF) Effective Date: 1/1/2024
- Place of Service Mismatch (PDF) Effective Date: 9/1/2018
- Polymerase Chain Reaction Respiratory Viral Panel Testing (CP.MP.181) (PDF)
- Postoperative Visits (PDF) Effective Date: 1/1/2014
- Preoperative Visits (PDF) Effective Date: 1/1/2014
- Problem-Oriented Visits with Surgical Procedures (PDF) Effective Date: 1/1/2024
- Pulmonary Function Testing (CP.MP.242) (PDF)
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (PDF)
- Skilled Nursing Facility Leveling (CC.PP.206) (PDF)
- Sleep Studies Place of Service (PDF) Effective Date: 6/1/2023
- Status "B" Bundled Services (PDF) Effective Date: 1/1/2014
- Status "P" Bundled Services (PDF) Effective Date: 3/15/2017
- Supplies Billed on Same Day As Surgery (PDF) Effective Date: 1/1/2013
- Testing for Select Genitourinary Conditions (CP.MP.97) (PDF)
- Thyroid Hormones and Insulin Testing in Pediatrics (CP.MP.154) (PDF)
- Ultrasound in Pregnancy (CP.MP.38) (PDF)
- Urine Specimen Validity Testing (PDF) Effective Date: 6/1/2023
- Urodynamic Testing (CP.MP.98) (PDF)
- Visits on Same Day as Surgery (PDF) Effective Date: 12/1/2022
- Visual Field Testing (PDF)
- Wheelchair Accessories (PDF) Effective Date: 6/1/2023
- Wheelchair Seating (CP.MP.99) (PDF)
- Wireless Motility Capsule (CP.MP.143) (PDF)
Pharmacy Policies
- Abaloparatide (Tymlos) (CP.PHAR.345) (PDF)
- Abemaciclib (Verzenio) (CP.PHAR.355) (PDF)
- Abiraterone (Zytiga, Yonsa) (CP.PHAR.84) (PDF)
- AbobotulinumtoxinA (Dysport) (CP.PHAR.230) (PDF)
- Abrocitinib (Cibinqo) (CP.PHAR.578) (PDF)
- Acalabrutinib (Calquence) (CP.PHAR.366) (PDF)
- Acoramidis (Attruby) (CP.PHAR.683) (PDF) Effective Date: 2/1/2025
- Acyclovir Buccal Tablet (Sitavig) (CP.PMN.210) (PDF)
- Adagrasib (Krazati) (CP.PHAR.605) (PDF)
- ADAMTS13, Recombinant-krhn (Adzynma) (CP.PHAR.635) (PDF)
- Adefovir (Hepsera) (CP.PHAR.142) (PDF)
- Ado-Trastuzumab Emtansine (Kadcyla) (CP.PHAR.229) (PDF)
- Aducanumab-avwa (Aduhelm) (CP.PHAR.468) (PDF)
- Afamelanotide (Scenesse) (CP.PHAR.444) (PDF)
- Afamitresgene Autoleucel (Tecelra) (CP.PHAR.678) (PDF)
- Afatinib (Gilotrif) (CP.PHAR.298) (PDF)
- Aflibercept (Eylea, Eylea HD), Aflibercept-yszy (Opuviz), Aflibercept-jbvf (Yesafili), Aflibercept-mrbb (Ahzantive) (CP.PHAR.184) (PDF)
- Agalsidase Beta (Fabrazyme) (PDF)
- Age Limit Override (Codeine, Tramadol, Hydrocodone) (CP.PMN.138) (PDF)
- Alectinib (Alecensa) (CP.PHAR.369) (PDF)
- Alemtuzumab (Lemtrada) (CP.PHAR.243) (PDF)
- Alendronate (Binosto, Fosamax Plus D) (CP.PMN.88) (PDF)
- Alglucosidase Alfa (Lumizyme) (CP.PHAR.160) (PDF)
- Allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen-dsat (StrataGraft) (CP.PHAR.562) (PDF)
- Allogenic Processed Thymus Tissue-agdc (Rethymic) (CP.PHAR.563) (PDF)
- Alpelisib (Piqray, Vijoice) (CP.PHAR.430) (PDF)
- Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) (CP.PHAR.94) (PDF)
- Amantadine ER (Gocovri, Osmolex ER) (CP.PMN.89) (PDF)
- Ambrisentan (Letairis) (CP.PHAR.190) (PDF)
- Amifampridine (Firdapse) (CP.PHAR.411) (PDF)
- Amikacin (Arikayce) (CP.PHAR.401) (PDF)
- Amisulpride (Barhemsys) (CP.PMN.236) (PDF)
- Amivantamab-vmjw (Rybrevant) (CP.PHAR.544) (PDF)
- Anifrolumab-fnia (Saphnelo) (CP.PHAR.551) (PDF)
- Anti-Inhibitor Coagulant Complex, Human (Feiba) (CP.PHAR.217) (PDF)
- Antithrombin III (ATryn, Thrombate III) (CP.PHAR.564) (PDF)
- Antithymocyte Globulin (Atgam, Thymoglobulin) (CP.PHAR.506) (PDF)
- Apalutamide (Erleada) (CP.PCH.45) (PDF)
- Apomorphine (Apokyn) (CP.PHAR.488) (PDF)
- Aprepitant (Aponvie, Emend, Cinvanti), Fosaprepitant (Emend for injection, Focinvez) (CP.PMN.19) (PDF)
- Aprocitentan (Tryvio) (CP.PHAR.676) (PDF)
- Aripiprazole Long-Acting Injections (Abilify Maintena, Abilify Asimtufii, Aristada, Aristada Initio) (CP.PHAR.290) (PDF)
- Aripiprazole Orally Disintegrating Tablet (CP.PCH.37) (PDF)
- Armodafinil (Nuvigil) (CP.PMN.35) (PDF)
- Asciminib (Scemblix) (CP.PHAR.565) (PDF)
- Asenapine (Saphris, Secuado) (CP.PMN.15) (PDF)
- Asfotase Alfa (Strensiq) (CP.PHAR.328) (PDF)
- Aspirin/Dipyridamole (Aggrenox) (CP.PMN.20) (PDF)
- Atezolizumab (Tecentriq) (CP.PHAR.235) (PDF)
- Atidarsagene Autotemcel (Lenmeldy) (CP.PHAR.602) (PDF)
- Atogepant (Qulipta) (CP.PHAR.566) (PDF)
- Avacincaptad Pegol (Izervay) (CP.PHAR.641) (PDF)
- Avacopan (Tavneos) (CP.PHAR.515) (PDF)
- Avalglucosidase Alfa-ngpt (Nexviazyme) (CP.PHAR.521) (PDF)
- Avapritinib (Ayvakit) (CP.PHAR.454) (PDF)
- Avatrombopag (Doptelet) (CP.PHAR.130) (PDF)
- Avelumab (Bavencio) (CP.PHAR.333) (PDF)
- Axatilimab-csfr (Niktimvo) (CP.PHAR.691) (PDF)
- Axicabtagene Ciloleucel (Yescarta) (CP.PHAR.362) (PDF)
- Axitinib (Inlyta) (CP.PHAR.100) (PDF)
- Azacitidine (Onureg, Vidaza) (CP.PHAR.387) (PDF)
- Azelaic Acid (Finacea Topical Gel/Foam) (HIM.PA.119) (PDF)
- Aztreonam (Cayston) (CP.PHAR.209) (PDF)
- Baclofen (Fleqsuvy, Gablofen, Lioresal, Lyvispah, Ozobax/Ozobax DS) (CP.PHAR.149) (PDF)
- Baloxavir Marboxil (Xofluza) (CP.PMN.185) (PDF)
- Bedaquiline (Sirturo) (CP.PMN.212) (PDF)
- Belatacept (Nulojix) (CP.PHAR.201) (PDF)
- Belimumab (Benlysta) (CP.PHAR.88) (PDF)
- Belinostat (Beleodaq) (CP.PHAR.311) (PDF)
- Belumosudil (Rezurock) (CP.PHAR.552) (PDF)
- Belzutifan (Welireg) (CP.PHAR.553) (PDF)
- Bempedoic Acid (Nexletol), Bempedoic Acid/Ezetimibe (Nexlizet) (CP.PMN.237) (PDF)
- Bendamustine (Belrapzo, Bendeka, Treanda, Vivimusta) (CP.PHAR.307) (PDF)
- Benralizumab (Fasenra) (HIM.PA.SP70) (PDF)
- Benznidazole (CP.PMN.90) (PDF)
- Berdazimer (Zelsuvmi) (CP.PMN.293) (PDF)
- Beremagene geperpavec-svdt (Vyjuvek) (CP.PHAR.592) (PDF)
- Berotralstat (Orladeyo) (HIM.PA.169) (PDF)
- Betaine (Cystadane) (CP.PHAR.143) (PDF)
- Betamethasone Dipropionate Spray (Sernivo) (CP.PMN.182) (PDF)
- Betibeglogene Autotemcel (Zynteglo) (CP.PHAR.545) (PDF)
- Bevacizumab (Alymsys, Avastin, Avzivi, Mvasi, Vegzelma, Zirabev) (CP.PHAR.93) (PDF)
- Bexarotene (Targretin Capsules, Gel) (CP.PHAR.75) (PDF)
- Bezlotoxumab (Zinplava) (CP.PHAR.300) (PDF)
- Bimatoprost Implant (Durysta) (CP.PHAR.486) (PDF)
- Binimetinib (Mektovi) (CP.PHAR.50) (PDF)
- Biologic and Non-biologic DMARDs (HIM.PA.SP60) (PDF)
- Birch Triterpenes (Filsuvez) (CP.PHAR.669) (PDF)
- Blinatumomab (Blincyto) (CP.PHAR.312) (PDF)
- Bortezomib (Velcade) (CP.PHAR.410) (PDF)
- Bosentan (Tracleer) (CP.PHAR.191) (PDF)
- Bosutinib (Bosulif) (CP.PHAR.105) (PDF)
- Brand Name Override and Non-Formulary Medications (HIM.PA.103) (PDF)
- Brentuximab Vedotin (Adcetris) (CP.PHAR.303) (PDF)
- Brexanolone (Zulresso) (CP.PHAR.417) (PDF)
- Brexpiprazole (Rexulti) (CP.PMN.68) (PDF)
- Brexucabtagene Autoleucel (Tecartus) (CP.PHAR.472) (PDF)
- Brigatinib (Alunbrig) (CP.PHAR.342) (PDF)
- Brimonidine Tartrate (Mirvaso) (CP.PMN.192) (PDF)
- Brinzolamide/Brimonidine (Simbrinza) (HIM.PA.15) (PDF)
- Brivaracetam (Briviact) (CP.PMN.297) (PDF)
- Brolucizumab-dbll (Beovu) (CP.PHAR.445) (PDF)
- Budesonide (Eohilia, Uceris) (CP.PMN.294) (PDF)
- Budesonide (Tarpeyo) (CP.PHAR.572) (PDF)
- Buprenorphine (Subutex) (CP.PMN.82) (PDF)
- Buprenorphine Injection (Sublocade, Brixadi) (CP.PHAR.289) (PDF)
- Buprenorphine/Naloxone (Suboxone, Zubsolv) (CP.PMN.81) (PDF)
- Bupropion/Naltrexone (Contrave) (CP.PCH.12) (PDF)
- Burosumab-twza (Crysvita) (CP.PHAR.11) (PDF)
- Butorphanol Nasal Spray (HIM.PA.46) (PDF)
- C1 Esterase Inhibitors (Berinert, Cinryze, Haegarda, Ruconest) (HIM.PA.170) (PDF)
- Cabazitaxel (Jevtana) (PDF)
- Cabotegravir (Apretude), Cabotegravir/Rilpivirine (Cabenuva) (CP.PHAR.573) (PDF)
- Cabozantinib (Cabometyx, Cometriq) (CP.PHAR.111) (PDF)
- Calcifediol (Rayaldee) (CP.PMN.76) (PDF)
- Calcipotriene/Betamethasone Dipropionate Foam (Enstilar) (CP.PMN.181) (PDF)
- Canakinumab (Ilaris) (CP.PHAR.246) (PDF)
- Cannabidiol (Epidiolex) (CP.PMN.164) (PDF)
- Capecitabine (Xeloda) (CP.PHAR.60) (PDF)
- Capivasertib (Truqap) (CP.PHAR.663) (PDF)
- Caplacizumab-yhdp (Cablivi) (CP.PHAR.416) (PDF)
- Capmatinib (Tabrecta) (CP.PHAR.494) (PDF)
- Carbidopa/Levodopa ER Capsules (Rytary), Enteral Suspension (Duopa), IR Tablets (Dhivy) (CP.PMN.238) (PDF)
- Carfilzomib (Kyprolis) (CP.PHAR.309) (PDF)
- Carglumic Acid (Carbaglu) (CP.PHAR.206) (PDF)
- Cariprazine (Vraylar) (CP.PMN.91) (PDF)
- Casimersen (Amondys 45) (CP.PHAR.470) (PDF)
- Celecoxib (Celebrex, Elyxyb) (CP.PMN.122) (PDF)
- Cemiplimab-rwlc (Libtayo) (CP.PHAR.397) (PDF)
- Cenegermin-bkbj (Oxervate) (CP.PMN.186) (PDF)
- Cenobamate (Xcopri) (CP.PMN.231) (PDF)
- Ceritinib (Zykadia) (CP.PHAR.349) (PDF)
- Cerliponase Alfa (Brineura) (CP.PHAR.338) (PDF)
- Cetuximab (Erbitux) (CP.PHAR.317) (PDF)
- Chenodiol (Chenodal) (CP.PMN.239) (PDF)
- Chlorambucil (Leukeran) (CP.PHAR.554) (PDF)
- Chloramphenicol Sodium Succinate (CP.PHAR.388) (PDF)
- Cholic Acid (Cholbam) (CP.PHAR.390) (PDF)
- Ciclopirox Topical Solution 8% (PDF)
- Ciltacabtagene Autoleucel (Carvykti) (CP.PHAR.533) (PDF)
- Cinacalcet (Sensipar) (CP.PHAR.61) (PDF)
- Cipaglucosidase Alfa-atga + Miglustat (Pombiliti + Opfolda) (CP.PHAR.567) (PDF)
- Ciprofloxacin/Dexamethasone (Ciprodex) (CP.PMN.248) (PDF)
- Ciprofloxacin/Fluocinolone (Otovel) (CP.PMN.249) (PDF)
- Cladribine (Mavenclad) (CP.PHAR.422) (PDF)
- Clascoterone (Winlevi) (CP.PMN.257) (PDF)
- Clobazam (Onfi, Sympazan) (CP.PMN.54) (PDF)
- CNS Stimulants (CP.PMN.92) (PDF)
- Cobimetinib (Cotellic) (CP.PHAR.380) (PDF)
- Colchicine (Colcrys, Lodoco) (CP.PMN.123) (PDF)
- Colesevelam (Welchol) (CP.PMN.250) (PDF)
- Collagenase Clostridium Histolyticum (Xiaflex) (CP.PHAR.82) (PDF)
- Colonoscopy Preparation Products (CP.PCH.43) (PDF)
- Compounded Medications (CP.PMN.280) (PDF)
- Conjugated Estrogens/Bazedoxifene (Duavee) (CP.PMN.258) (PDF)
- Continuous Glucose Monitors (CP.PMN.214) (PDF)
- Copanlisib (Aliqopa) (CP.PHAR.357) (PDF)
- Corticosteroids for Ophthalmic Injection (Dextenza, Iluvien, Ozurdex, Retisert, Xipere, Yutiq) (CP.PHAR.385) (PDF)
- Cosibelimab-lpdl (Unloxcyt) (CP.PHAR.711) (PDF) Effective Date: 3/1/2025
- Cosyntropin (Cortrosyn) (CP.PHAR.203) (PDF)
- Crinecerfont (Crenessity) (CP.PHAR.692) (PDF) Effective Date: 2/1/2025
- Crisaborole (Eucrisa) (CP.PMN.110) (PDF)
- Crizanlizumab-tmca (Adakveo) (CP.PHAR.449) (PDF)
- Crizotinib (Xalkori) (CP.PHAR.90) (PDF)
- Crovalimab-akkz (PiaSky) (CP.PHAR.664) (PDF)
- Cyclosporine (Cequa, Restasis, Verkazia, Vevye, Klarity-C) (CP.PMN.48) (PDF)
- Cysteamine Ophthalmic (Cystaran, Cystadrops) (CP.PMN.130) (PDF)
- Cysteamine oral (Cystagon, Procysbi) (CP.PHAR.155) (PDF)
- Cytomegalovirus Immune Globulin (CytoGam) (CP.PHAR.277) (PDF)
- Dabrafenib (Tafinlar) (CP.PHAR.239) (PDF)
- Dacomitinib (Vizimpro) (CP.PHAR.399) (PDF)
- Dalfampridine (Ampyra) (CP.PHAR.248) (PDF)
- Dalteparin (Fragmin) (CP.PHAR.225) (PDF)
- Danicopan (Voydeya) (CP.PHAR.665) (PDF)
- Dapsone (Aczone Gel) (CP.PCH.32) (PDF)
- Daptomycin (Cubicin, Cubicin RF, Dapzura RT) (CP.PHAR.351) (PDF)
- Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro) (CP.PHAR.310) (PDF)
- Darbepoetin Alfa (Aranesp) (CP.PHAR.236) (PDF)
- Darolutamide (Nubeqa) (CP.PHAR.435) (PDF)
- Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira Pak) (HIM.PA.SP61) (PDF)
- Dasatinib (Sprycel, Phyrago) (CP.PHAR.72) (PDF)
- Datopotamab Deruxtecan-dlnk (Datroway) (CP.PHAR.715) (PDF)
- Daunorubicin/Cytarabine (Vyxeos) (CP.PHAR.352) (PDF)
- DaxibotulinumtoxinA-lanm (Daxxify) (CP.PHAR.651) (PDF)
- Decitabine/Cedazuridine (Inqovi) (CP.PHAR.479) (PDF)
- Deferasirox (Exjade, Jadenu) (CP.PHAR.145) (PDF)
- Deferoxamine (Desferal) (CP.PHAR.146) (PDF)
- Deflazacort (Emflaza) (CP.PHAR.331) (PDF)
- Degarelix Acetate (Firmagon) (CP.PHAR.170) (PDF)
- Delafloxacin (Baxdela) (CP.PMN.115) (PDF)
- Delandistrogene Moxeparvovec-rokl (Elevidys) (CP.PHAR.593) (PDF)
- Denileukin Diftitox-cxdl (Lymphir) (CP.PHAR.693) (PDF)
- Denosumab (Prolia, Xgeva), Denosumab-bbdz (Jubbonti, Wyost) (CP.PHAR.58) (PDF)
- Desmopressin Acetate (DDAVP, Stimate, Nocdurna) (CP.PHAR.214) (PDF)
- Deutetrabenazine (Austedo, Austedo XR) (CP.PCH.42) (PDF)
- Dexrazoxane (Totect) (CP.PHAR.418) (PDF)
- Dextromethorphan/Bupropion (Auvelity) (CP.PMN.284) (PDF)
- Dextromethorphan-Quinidine (Nuedexta) (CP.PMN.93) (PDF)
- Diazepam (Libervant, Valtoco) (CP.PMN.216) (PDF)
- Dichlorphenamide (Keveyis) (CP.PMN.261) (PDF)
- Diclofenac (Cambia, Flector, Licart, Pennsaid, Solaraze, Zipsor, Zorvolex) (CP.PCH.28) (PDF)
- Dimethyl Fumarate (Tecfidera), Diroximel Fumarate (Vumerity), Monomethyl Fumarate (Bafiertam) (CP.PHAR.249) (PDF)
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (HIM.PA.58) (PDF)
- Dolasetron (Anzemet) (CP.PMN.141) (PDF)
- Donanemab (Kinsunla) (CP.PHAR.594) (PDF)
- Dornase Alfa (Pulmozyme) (CP.PHAR.212) (PDF)
- Dostarlimab-gxly (Jemperli) (CP.PHAR.540) (PDF)
- Doxepin (Silenor, Prudoxin, Zonalon) (HIM.PA.147) (PDF)
- Doxycycline Hyclate (Acticlate, Doryx), Doxycycline (Oracea) (CP.PMN.79) (PDF)
- Dupilumab (Dupixent) (HIM.PA.SP69) (PDF)
- Durvalumab (Imfinzi) (CP.PHAR.339) (PDF)
- Dutasteride (Avodart), Dutasteride/Tamsulosin (Jalyn) (CP.PMN.128) (PDF)
- Duvelisib (Copiktra) (CP.PHAR.400) (PDF)
- Ecallantide (Kalbitor) (CP.PHAR.177) (PDF)
- Eculizumab (Soliris) (CP.PHAR.97) (PDF)
- Edaravone (Radicava, Radivaca ORS) (CP.PHAR.343) (PDF)
- Efgartigimod Alfa-fcab, Efgartigimod/Hyaluronidase-qvfc (Vyvgart, Vyvgart Hytrulo) (CP.PHAR.555) (PDF)
- Efinaconazole (Jublia) (CP.PMN.25) (PDF)
- Eflornithine (Iwilfin) (CP.PHAR.670) (PDF)
- Elacestrant (Orserdu) (CP.PHAR.623) (PDF)
- Eladocagene Exuparvovec-tneq (Kebilidi) (CP.PHAR.595) (PDF) Effective Date: 3/1/2025
- Elafibranor (Iqirvo) (CP.PHAR.688) (PDF)
- Elagolix (Orilissa), Elagolix/Estradiol/Norethinedrone (Oriahnn) (CP.PHAR.136) (PDF)
- Elapegademase-lvlr (Revcovi) (CP.PHAR.419) (PDF)
- Elbasvir/Grazoprevir (Zepatier) (HIM.PA.SP62) (PDF)
- Elexacaftor/Ivacaftor/Tezacaftor; Ivacaftor (Trikafta) (CP.PHAR.440) (PDF)
- Eliglustat (Cerdelga) (CP.PHAR.153) (PDF)
- Elivaldogene Autotemcel (Skysona) (CP.PHAR.556) (PDF)
- Elosulfase Alfa (Vimizim) (CP.PHAR.162) (PDF)
- Elotuzumab (Empliciti) (CP.PHAR.308) (PDF)
- Elranatamab-bcmm (Elrexfio) (CP.PHAR.652) (PDF)
- Eltrombopag (Alvaiz, Promacta) (CP.PHAR.180) (PDF)
- Eluxadoline (Viberzi) (CP.PMN.170) (PDF)
- Emapalumab-lzsg (Gamifant) (CP.PHAR.402) (PDF)
- Emicizumab-kxwh (Hemlibra) (CP.PHAR.370) (PDF)
- Emtricitabine/Tenofovir Alafenamide (Descovy) (CP.PMN.235) (PDF)
- Enasidenib (Idhifa) (CP.PHAR.363) (PDF)
- Encorafenib (Braftovi) (CP.PHAR.127) (PDF)
- Enfortumab Vedotin-ejfv (Padcev) (CP.PHAR.455) (PDF)
- Enfuvirtide (Fuzeon) (CP.PHAR.41) (PDF)
- Enoxaparin (Lovenox) (CP.PHAR.224) (PDF)
- Ensartinib (Ensacove) (CP.PHAR.712) (PDF) Effective Date: 3/1/2025
- Entecavir (Baraclude) (HIM.PA.08) (PDF)
- Entrectinib (Rozlytrek) (CP.PHAR.441) (PDF)
- Enzalutamide (Xtandi) (CP.PHAR.106) (PDF)
- Epcoritamab-bysp (Epkinly) (CP.PHAR.634) (PDF)
- Epinephrine (EpiPen, EpiPen Jr, Auvi-Q, Neffy) (CP.PCH.55) (PDF)
- Eplontersen (Wainua) (CP.PHAR.633) (PDF)
- Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) (CP.PHAR.237) (PDF)
- Epoprostenol (Flolan, Veletri) (CP.PHAR.192) (PDF)
- Eptinezumab-jjmr (Vyepti) (HIM.PA.SP64) (PDF)
- Erdafitinib (Balversa) (CP.PHAR.423) (PDF)
- Erenumab-aooe (Aimovig) (HIM.PA.SP65) (PDF)
- Eribulin Mesylate (Halaven) (CP.PHAR.318) (PDF)
- Erlotinib (Tarceva) (CP.PHAR.74) (PDF)
- Erwinia Asparaginase (Rylaze) (CP.PHAR.301) (PDF)
- Esketamine (Spravato) (CP.PMN.199) (PDF)
- Estradiol Vaginal Ring (Femring) (CP.PMN.263) (PDF)
- Etelcalcetide (Parsabiv) (CP.PHAR.379) (PDF)
- Eteplirsen (Exondys 51) (CP.PHAR.288) (PDF)
- Etranacogene Dezaparvovec-drlb (Hemgenix) (CP.PHAR.580) (PDF)
- Everolimus (Afinitor, Afinitor Disperz, Zortress) (CP.PHAR.63) (PDF)
- Evinacumab-dgnb (Evkeeza) (HIM.PA.166) (PDF)
- Evolocumab (Repatha) (HIM.PA.156) (PDF)
- Exagamglogene Autotemcel (Casgevy) (CP.PHAR.603) (PDF)
- Factor IX (Human, Recombinant) (CP.PHAR.218) (PDF)
- Factor IX Complex, Human (Profilnine) (CP.PHAR.219) (PDF)
- Factor VIIa, Recombinant (NovoSeven RT, SevenFact) (CP.PHAR.220) (PDF)
- Factor VIII (Human, Recombinant) (CP.PHAR.215) (PDF)
- Factor VIII/von Willebrand Factor Complex (Human – Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant – Vonvendi) (CP.PHAR.216) (PDF)
- Factor XIII A-Subunit, Recombinant (Tretten) (CP.PHAR.222) (PDF)
- Factor XIII, Human (Corifact) (CP.PHAR.221) (PDF)
- Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (CP.PHAR.456) (PDF)
- Faricimab-svoa (Vabysmo) (CP.PHAR.581) (PDF)
- Febuxostat (Uloric) (CP.PMN.57) (PDF)
- Fecal Microbiota Spores, Live-brpk (Vowst) (CP.PHAR.632) (PDF)
- Fecal Microbiota, Live-jslm (Rebyota) (CP.PHAR.613) (PDF)
- Fedratinib (Inrebic) (CP.PHAR.442) (PDF)
- Fenfluramine (Fintepla) (CP.PMN.246) (PDF)
- Fentanyl IR (Actiq, Fentora, Lazanda, Subsys) (CP.PMN.127) (PDF)
- Ferric Carboxymaltose (Injectafer) (CP.PHAR.234) (PDF)
- Ferric Derisomaltose (Monoferric) (CP.PHAR.480) (PDF)
- Ferric Maltol (Accrufer) (CP.PMN.213) (PDF)
- Ferumoxytol (Feraheme) (CP.PHAR.165) (PDF)
- Fezolinetant (Veozah) (CP.PMN.289) (PDF)
- Fibrinogen Concentrate [Human] (Fibryga, RiaSTAP) (CP.PHAR.526) (PDF)
- Fidanacogene Elaparvovec-dzkt (Beqvez) (CP.PHAR.643) (PDF)
- Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix), Filgrastim-aafi (Nivestym), Filgrastim-ayow (Releuko), Filgrastim-txid (Nypozi) (CP.PHAR.297) (PDF)
- Finerenone (Kerendia) (CP.PMN.266) (PDF)
- Fingolimod (Gilenya, Tascenso ODT) (CP.PCH.38) (PDF)
- Fitusiran (Qfitlia) (CP.PHAR.706) (PDF)
- Flibanserin (Addyi) (CP.PHAR.446) (PDF)
- Fluorouracil Cream (Tolak) (CP.PMN.165) (PDF)
- Fluticasone Propionate (Xhance) (CP.PMN.95) (PDF)
- Fondaparinux (Arixtra) (CP.PHAR.226) (PDF)
- Fosdenopterin (Nulibry) (CP.PHAR.471) (PDF)
- Fostamatinib (Tavalisse) (CP.PHAR.24) (PDF)
- Fostemsavir (Rukobia) (CP.PHAR.516) (PDF)
- Fremanezumab-vfrm (Ajovy) (HIM.PA.SP66) (PDF)
- Fruquintinib (Fruzaqla) (CP.PHAR.666) (PDF)
- Fulvestrant (Faslodex Injection) (CP.PHAR.424) (PDF)
- Furosemide (Furoscix) (CP.PHAR.608) (PDF)
- Futibatinib (Lytgobi) (CP.PHAR.604) (PDF)
- Gabapentin ER (Gralise, Horizant) (CP.PMN.240) (PDF)
- Galcanezumab-gnlm (Emgality) (HIM.PA.SP67) (PDF)
- Galsulfase (Naglazyme) (CP.PHAR.161) (PDF)
- Ganaxolone (Ztalmy) (CP.PMN.278) (PDF)
- Gefitinib (Iressa) (CP.PHAR.68) (PDF)
- Gemtuzumab Ozogamicin (Mylotarg) (CP.PHAR.358) (PDF)
- Gilteritinib (Xospata) (CP.PHAR.412) (PDF)
- Givinostat (Duvyzat) (CP.PHAR.644) (PDF)
- Givosiran (Givlaari) (CP.PHAR.457) (PDF)
- Glasdegib (Daurismo) (CP.PHAR.413) (PDF)
- Glatiramer Acetate (Copaxone, Glatopa) (CP.PHAR.252) (PDF)
- Glaucoma Agents (CP.PMN.286) (PDF)
- Glecaprevir/Pibrentasvir (Mavyret) (HIM.PA.SP36) (PDF)
- Glofitamab-gxbm (Columvi) (CP.PHAR.636) (PDF)
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (HIM.PA.53) (PDF)
- Glycerol Phenylbutyrate (Ravicti) (CP.PHAR.207) (PDF)
- Golodirsen (Vyondys 53) (CP.PHAR.453) (PDF)
- Goserelin Acetate (Zoladex) (CP.PHAR.171) (PDF)
- Granisetron (Sancuso, Sustol) (CP.PMN.74) (PDF)
- Halcinonide (Halog) (HIM.PA.20) (PDF)
- Halobetasol Propionate (Bryhali, Lexette, Ultravate) (CP.PMN.180) (PDF)
- Halobetasol Propionate/Tazarotene (Duobrii) (CP.PMN.208) (PDF)
- Hemin (Panhematin) (CP.PHAR.181) (PDF)
- Histrelin Acetate (Vantas, Supprelin LA) (CP.PHAR.172) (PDF)
- House Dust Mite Allergen Extract (Odactra) (CP.PMN.111) (PDF)
- Human Growth Hormone (Somapacitan, Somatrogon, Somatropin) (HIM.PA.161) (PDF)
- Hyaluronate Derivatives (CP.PHAR.05) (PDF)
- Hydroxyurea (Siklos, Xromi) (CP.PMN.193) (PDF)
- Ibalizumab-uiyk (Trogarzo) (CP.PHAR.378) (PDF)
- Ibandronate Injection (Boniva) (CP.PHAR.189) (PDF)
- Ibrutinib (Imbruvica) (CP.PHAR.126) (PDF)
- Ibuprofen/Famotidine (Duexis) (CP.PMN.120) (PDF)
- Icatibant (Firazyr) (CP.PHAR.178) (PDF)
- Icosapent Ethyl (Vascepa) (CP.PMN.187) (PDF)
- Idecabtagene Vicleucel (Abecma) (CP.PHAR.481) (PDF)
- Idelalisib (Zydelig) (CP.PHAR.133) (PDF)
- Idursulfase (Elaprase) (CP.PHAR.156) (PDF)
- Iloperidone (Fanapt) (CP.PMN.32) (PDF)
- Iloprost (Ventavis) (CP.PHAR.193) (PDF)
- Imatinib (Gleevec) (CP.PHAR.65) (PDF)
- Imetelstat (Rytelo) (CP.PHAR.690) (PDF)
- Imiglucerase (Cerezyme) (CP.PHAR.154) (PDF)
- Immune Globulins (CP.PHAR.103) (PDF)
- Inavolisib (Itovebi) (CP.PHAR.702) (PDF)
- Inclisiran (Leqvio) (CP.PHAR.568) (PDF)
- IncobotulinumtoxinA (Xeomin) (CP.PHAR.231) (PDF)
- Inebilizumab-cdon (Uplizna) (CP.PHAR.458) (PDF)
- Infertility and Fertility Preservation (CP.PHAR.131) (PDF)
- Infigratinib (Truseltiq) (CP.PHAR.547) (PDF)
- Inhaled Agents for Asthma and COPD (HIM.PA.153) (PDF)
- Inotersen (Tegsedi) (CP.PHAR.405) (PDF)
- Inotuzumab Ozogamicin (Besponsa) Reference Number: CP.PHAR.359 Effective Date: 09.26.17 Last Review Date: 11.24 Line of Business: Commercial, HIM, Medicaid (CP.PHAR.359) (PDF)
- Insulin Delivery Systems (V-Go, Omnipod, InPen) (CP.PHAR.534) (PDF)
- Insulin detemir (Levemir) (HIM.PA.171) (PDF)
- Insulin Glargine (Rezvoglar, Semglee, Toujeo) (HIM.PA.09) (PDF)
- Interferon Beta-1a (Avonex, Rebif) (CP.PHAR.255) (PDF)
- Interferon Beta-1b (Betaseron, Extavia) (CP.PCH.46) (PDF)
- Interferon Gamma- 1b (Actimmune) (CP.PHAR.52) (PDF)
- Iobenguane I-131 (Azedra) (CP.PHAR.459) (PDF)
- Ipilimumab (Yervoy) (CP.PHAR.319) (PDF)
- Iptacopan (Fabhalta) (CP.PHAR.656) (PDF)
- Irinotecan Liposome (Onivyde) (CP.PHAR.304) (PDF)
- Isatuximab-irfc (Sarclisa) (CP.PHAR.482) (PDF)
- Isavuconazonium (Cresemba) (CP.PMN.154) (PDF)
- Isotretinoin (Absorica, Absorica LD, Amnesteem, Claravis, Myorisan, Zenatane) (CP.PMN.143) (PDF)
- Istradefylline (Nourianz) (CP.PMN.217) (PDF)
- Itraconazole (Sporanox, Tolsura) (CP.PMN.124) (PDF)
- Ivabradine (Corlanor) (CP.PMN.70) (PDF)
- Ivacaftor (Kalydeco) (CP.PHAR.210) (PDF)
- Ivermectin (Stromectol, Sklice) (CP.PMN.269) (PDF)
- Ivosidenib (Tibsovo) (CP.PHAR.137) (PDF)
- Ixazomib (Ninlaro) (CP.PHAR.302) (PDF)
- Ketamine (Ketalar) (CP.PMN.296) (PDF)
- Ketorolac Nasal Spray (Sprix) (CP.PMN.282) (PDF)
- Lanadelumab-fylo (Takhzyro) (HIM.PA.172) (PDF)
- Lanreotide (Somatuline Depot and Unbranded) (CP.PHAR.391) (PDF)
- Lapatinib (Tykerb) (CP.PHAR.79) (PDF)
- Laronidase (Aldurazyme) Reference Number: CP.PHAR.152 Effective Date: 02.01.16 Last Review Date: 05.24 Line of Business: Commercial, HIM, Medicaid (CP.PHAR.152) (PDF)
- Larotrectinib (Vitrakvi) (CP.PHAR.414) (PDF)
- Lasmiditan (Reyvow) (CP.PMN.218) (PDF)
- Lazertinib (Lazcluze) (CP.PHAR.695) (PDF)
- Lebrikizumab (Ebglyss) (CP.PHAR.704) (PDF)
- Lecanemab-irmb (Leqembi) (CP.PHAR.596) (PDF)
- Ledipasvir/Sofosbuvir (Harvoni) (HIM.PA.SP3) (PDF)
- Lefamulin (Xenleta) (CP.PMN.219) (PDF)
- Lenacapavir (Sunlenca) (CP.PHAR.622) (PDF)
- Lenalidomide (Revlimid) (CP.PHAR.71) (PDF)
- Leniolisib (Joenja) (CP.PHAR.597) (PDF)
- Lenvatinib (Lenvima) (CP.PHAR.138) (PDF)
- Letermovir (Prevymis) (CP.PHAR.367) (PDF)
- Leucovorin Injection (CP.PHAR.393) (PDF)
- Leuprolide Acetate (Eligard, Fensolvi, Lupron Depot, Lupron Depot-Ped), Leuprolide mesylate (Camcevi) (CP.PCH.53) (PDF)
- Levacetylleucine (Aqneursa) (CP.PHAR.682) (PDF)
- Levodopa Inhalation Powder (Inbrija) (CP.PMN.267) (PDF)
- Levoketoconazole (Recorlev) (CP.PMN.275) (PDF)
- Levoleucovorin (Fusilev, Khapzory) (CP.PHAR.151) (PDF)
- Levomilnacipran (Fetzima) (HIM.PA.125) (PDF)
- L-glutamine (Endari) (CP.PMN.116) (PDF)
- Lidocaine Transdermal (Lidoderm, ZTlido) (CP.PMN.08) (PDF)
- Lifileucel (Amtagvi) (CP.PHAR.598) (PDF)
- Lifitegrast (Xiidra) (CP.PMN.73) (PDF)
- Linezolid (Zyvox) (CP.PMN.27) (PDF)
- Lisocabtagene Maraleucel (Breyanzi) (CP.PHAR.483) (PDF)
- Lofexidine (Lucemyra) (CP.PMN.152) (PDF)
- Lomustine (Gleostine) (CP.PHAR.507) (PDF)
- Lonafarnib (Zokinvy) (CP.PHAR.499) (PDF)
- Loncastuximab Tesirine-lpyl (Zynlonta) (CP.PHAR.539) (PDF)
- Long-term Antibiotic Treatment for Tick-borne Diseases (CP.PMN.279) (PDF)
- Lorlatinib (Lorbrena) (CP.PHAR.406) (PDF)
- Loteprednol etabonate (Eysuvis) (CP.PMN.260) (PDF)
- Lotilaner (Xdemvy) (CP.PMN.291) (PDF)
- Lovotibeglogene Autotemcel (Lyfgenia) (CP.PHAR.627) (PDF)
- Lubiprostone (Amitiza) (CP.PMN.142) (PDF)
- Luliconazole Cream (Luzu) (CP.PMN.166) (PDF)
- Lumacaftor/Ivacaftor (Orkambi) (CP.PHAR.213) (PDF)
- Lumasiran (Oxlumo) (CP.PHAR.473) (PDF)
- Lumateperone (Caplyta) (CP.PMN.232) (PDF)
- Lurbinectedin (Zepzelca) (CP.PHAR.500) (PDF)
- Luspatercept-aamt (Reblozyl) (CP.PHAR.450) (PDF)
- Lusutrombopag (Mulpleta) (CP.PHAR.407) (PDF)
- Lutetium Lu 177 Dotatate (Lutathera) (CP.PHAR.384) (PDF)
- Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) (CP.PHAR.582) (PDF)
- Macitentan (Opsumit) (CP.PHAR.194) (PDF)
- Mannitol (Bronchitol) (CP.PHAR.518) (PDF)
- Maralixibat (Livmarli) (CP.PHAR.543) (PDF)
- Margetuximab-cmkb (Margenza) (CP.PHAR.522) (PDF)
- Maribavir (Livtencity) (CP.PMN.271) (PDF)
- Mavacamten (Camzyos) (CP.PMN.272) (PDF)
- Mavorixafor (Xolremdi) (CP.PHAR.679) (PDF)
- Mecamylamine (Vecamyl) (CP.PMN.136) (PDF)
- Mecasermin (Increlex) (CP.PHAR.150) (PDF)
- Mechlorethamine Gel (Valchlor) (CP.PHAR.381) (PDF)
- Megestrol Acetate (CP.PMN.179) (PDF)
- Melphalan (Hepzato) (CP.PHAR.653) (PDF)
- Memantine ER (Namenda XR), Memantine/Donepezil (Namzaric) (CP.PCH.30) (PDF)
- Mepolizumab (Nucala) (CP.PHAR.200) (PDF)
- Mercaptopurine (Purixan) (CP.PHAR.447) (PDF)
- Metformin ER (Fortamet, Glumetza) (CP.PMN.72) (PDF)
- Methotrexate (Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo) (CP.PHAR.134) (PDF)
- Methoxsalen (Uvadex) (HIM.PA.17) (PDF)
- Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) (CP.PHAR.238) (PDF)
- Methylnaltrexone Bromide (Relistor) (CP.PMN.169) (PDF)
- Metoclopramide (Gimoti) (CP.PMN.252) (PDF)
- Metreleptin (Myalept) (CP.PHAR.425) (PDF)
- Midazolam (Nayzilam) (CP.PMN.211) (PDF)
- Midostaurin (Rydapt) (CP.PHAR.344) (PDF)
- Mifepristone (Korlym) (CP.PHAR.101) (PDF)
- Migalastat (Galafold) (CP.PHAR.394) (PDF)
- Miglustat (Zavesca) (CP.PHAR.164 ) (PDF)
- Milnacipran (Savella) (CP.PMN.125) (PDF)
- Minocycline ER (Solodyn, Ximino, Minolira), Microspheres (Arestin), Foam (Zilxi) (CP.PMN.80) (PDF)
- Mirdametinib (Gomekli) (CP.PHAR.718) (PDF)
- Mirvetuximab soravatansine-gynx (Elahere) (CP.PHAR.617) (PDF)
- Mitapivat (Pyrukynd) (CP.PHAR.558) (PDF)
- Mitomycin for Pyelocalyceal Solution (Jelmyto) (CP.PHAR.495) (PDF)
- Mitoxantrone (CP.PHAR.258) (PDF)
- Mobocertinib (Exkivity) (CP.PHAR.559) (PDF)
- Modafinil (Provigil) (CP.PMN.39) (PDF)
- Mogamulizumab-kpkc (Poteligeo) (CP.PHAR.139) (PDF)
- Momelotinib (Ojjaara) (CP.PHAR.654) (PDF)
- Mometasone (Nasonex) (HIM.PA.93) (PDF)
- Mometasone Furoate (Sinuva) (CP.PHAR.448) (PDF)
- Mosunetuzumab-axgb (Lunsumio) (CP.PHAR.618) (PDF)
- Motixafortide (Aphexda) (CP.PHAR.655) (PDF)
- Moxetumomab Pasudotox-tdfk (Lumoxiti) (CP.PHAR.398) (PDF)
- Nabumetone Double-Strength (Relafen DS) (CP.PMN.287) (PDF)
- Nadofaragene Firadenovec-vncg (Adstiladrin) (CP.PHAR.461) (PDF)
- Nafarelin Acetate (Synarel) (CP.PHAR.174) (PDF)
- Naldemedine (Symproic) (CP.PMN.112) (PDF)
- Nalmefene (Opvee) (CP.PHAR.638) (PDF)
- Naloxegol (Movantik) (HIM.PA.167) (PDF)
- Naltrexone (Vivitrol) (CP.PHAR.96) (PDF)
- Naproxen Oral Suspension (Naprosyn) (HIM.PA.130) (PDF)
- Naproxen/Esomeprazole (Vimovo) (CP.PMN.117) (PDF)
- Natalizumab (Tysabri), Natalizumab-sztn (Tyruko) (CP.PHAR.259) (PDF)
- Naxitamab-gqgk (Danyelza) (CP.PHAR.523) (PDF)
- Necitumumab (Portrazza) (CP.PHAR.320) (PDF)
- Nedosiran (Rivfloza) (CP.PHAR.619) (PDF)
- Nemolizumab-ilto (Nemluvio) (CP.PHAR.703) (PDF)
- Neomycin/Fluocinolone Cream (Neo-Synalar) (CP.PMN.167) (PDF)
- Neratinib (Nerlynx) (CP.PHAR.365) (PDF)
- Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) (CP.PMN.158) (PDF)
- Nifurtimox (Lampit) (CP.PMN.256) (PDF)
- Nilotinib (Tasigna) (CP.PHAR.76) (PDF)
- Nintedanib (Ofev) (CP.PHAR.285) (PDF)
- Niraparib (Zejula) (CP.PHAR.408) (PDF)
- Niraparib and Abiraterone Acetate (Akeega) (CP.PHAR.645) (PDF)
- Nirmatrelvir and Ritonavir (Paxlovid) (CP.PMN.288) (PDF)
- Nirogacestat (Ogsiveo) (CP.PHAR.671) (PDF)
- Nirsevimab-alip (Beyfortus) (CP.PHAR.614) (PDF)
- Nitazoxanide (Alinia) (HIM.PA.152) (PDF)
- Nitisinone (Nityr, Orfadin) (CP.PHAR.132) (PDF)
- Nivolumab (Opdivo) (CP.PHAR.121) (PDF)
- Nivolumab and Relatlimab-rmbw (Opdualag) (CP.PHAR.588) (PDF)
- No Coverage Criteria, Recent Label Changes Pending Clinical Policy Update (HIM.PA.33) (PDF)
- Nogapendekin Alfa Inbakicept-pmln (Anktiva) (CP.PHAR.684) (PDF)
- Non-Calcium Phosphate Binders (CP.PMN.04) (PDF)
- Non-Formulary and Formulary Contraceptives (HIM.PA.100) (PDF)
- Non-Formulary Test Strips (HIM.PA.34) (PDF)
- Nusinersen (Spinraza) (CP.PHAR.327) (PDF)
- Obecabtagene autoleucel (Aucatzyl) (CP.PHAR.675) (PDF) Effective Date: 3/1/2025
- Obeticholic Acid (Ocaliva) (CP.PHAR.287) (PDF)
- Obinutuzumab (Gazyva) (CP.PHAR.305) (PDF)
- Ocrelizumab (Ocrevus) (CP.PHAR.335) (PDF)
- Octreotide Acetate (Sandostatin, Sandostatin LAR Depot, Mycapssa) (CP.PHAR.40) (PDF)
- Odevixibat (Bylvay) (CP.PHAR.528) (PDF)
- Ofatumumab (Arzerra, Kesimpta) (CP.PHAR.306) (PDF)
- Off-Label Drug Use (HIM.PA.154) (PDF)
- Olanzapine Long-Acting Injection (Zyprexa Relprevv) (CP.PHAR.292) (PDF)
- Olanzapine/Samidorphan (Lybalvi) (CP.PMN.265) (PDF)
- Olaparib (Lynparza) (CP.PHAR.360) (PDF)
- Olipudase Alfa-rpcp (Xenpozyme) (CP.PHAR.586) (PDF)
- Olutasidenib (Rezlidhia) (CP.PHAR.615) (PDF)
- Omacetaxine (Synribo) (CP.PHAR.108) (PDF)
- Omadacycline (Nuzyra) (CP.PMN.188) (PDF)
- Omalizumab (Xolair) (CP.PCH.49) (PDF)
- Omaveloxolone (Skyclarys) (CP.PHAR.590) (PDF)
- OnabotulinumtoxinA (Botox) (CP.PHAR.232) (PDF)
- Onasemnogene Abeparvovec (Zolgensma) (CP.PHAR.421) (PDF)
- Ophthalmic Corticosteroids (HIM.PA.03) (PDF)
- Ophthalmic Riboflavin (Photrexa, Photrexa Viscous) (CP.PHAR.536) (PDF)
- Opicapone (Ongentys) (CP.PMN.245) (PDF)
- Opioid Analgesics* (HIM.PA.139) (PDF)
- Osilodrostat (Isturisa) (CP.PHAR.487) (PDF)
- Osimertinib (Tagrisso) (CP.PHAR.294) (PDF)
- Ospemifene (Osphena) (CP.PMN.168) (PDF)
- Overactive Bladder Agents (CP.PMN.198) (PDF)
- Oxymetazoline (Rhofade, Upneeq) (CP.PMN.86) (PDF)
- Ozanimod (Zeposia) (CP.PHAR.462) (PDF)
- Ozenoxacin (Xepi) (CP.PMN.119) (PDF)
- Paclitaxel, Protein-Bound (Abraxane) (CP.PHAR.176) (PDF)
- Pacritinib (Vonjo) (CP.PHAR.583) (PDF)
- Palbociclib (Ibrance) (HIM.PA.173) (PDF)
- Paliperidone Long-Acting Injections (Invega Hafyera, Invega Sustenna, Invega Trinza) (CP.PHAR.291) (PDF)
- Palivizumab (Synagis) (CP.PHAR.16) (PDF)
- Palopegteriparatide (Yorvipath) (CP.PHAR.696) (PDF)
- Palovarotene (Sohonos) (CP.PHAR.548) (PDF)
- Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep) (CP.PCH.44) (PDF)
- Panitumumab (Vectibix) (CP.PHAR.321) (PDF)
- Parathyroid Hormone (Natpara) (CP.PHAR.282) (PDF)
- Paricalcitol Injection (Zemplar) (CP.PHAR.270) (PDF)
- Pasireotide (Signifor, Signifor LAR) (CP.PHAR.332) (PDF)
- Patiromer (Veltassa) (CP.PMN.205) (PDF)
- Patisiran (Onpattro) (CP.PHAR.395) (PDF)
- Pazopanib (Votrient) (CP.PHAR.81) (PDF)
- Peanut Allergen Powder-dnfp (Palforzia) (CP.PMN.220) (PDF)
- Pegaspargase (Oncaspar), Calaspargase Pegol-mknl (Asparlas) (CP.PHAR.353) (PDF)
- Pegcetacoplan (Empaveli, Syfovre) (CP.PHAR.5240 (PDF)
- Pegfilgrastim/Biosimilars, Eflapegrastim, Efbemalenograstim (CP.PHAR.296) (PDF)
- Peginterferon Alfa-2a (Pegasys) (CP.PHAR.89) (PDF)
- Peginterferon Beta-1a (Plegridy) (CP.PHAR.271) (PDF)
- Pegloticase (Krystexxa) (CP.PHAR.115) (PDF)
- Pegunigalsidase Alfa-iwxj (Elfabrio) (CP.PHAR.512) (PDF)
- Pegvaliase-pqpz (Palynziq) (CP.PHAR.140) (PDF)
- Pegvisomant (Somavert) (CP.PHAR.389) (PDF)
- Pembrolizumab (Keytruda) (CP.PHAR.322) (PDF)
- Pemetrexed (Alimta, Pemfexy) (CP.PHAR.368) (PDF)
- Pemigatinib (Pemazyre) (CP.PHAR.496) (PDF)
- Penicillamine (Cuprimine) (CP.PCH.09) (PDF)
- Perampanel (Fycompa) (CP.PMN.156) (PDF)
- Perfluorohexyloctane (Miebo) (CP.PMN.290) (PDF)
- Pertuzumab (Perjeta) (CP.PHAR.227) (PDF)
- Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (Phesgo) (CP.PHAR.501) (PDF)
- Pexidartinib (Turalio) (CP.PHAR.436) (PDF)
- Phendimetrazine (CP.PCH.47) (PDF)
- Phentermine (Adipex-P, Lomaira) (CP.PCH.13) (PDF)
- Pilocarpine (Qlosi, Vuity) (CP.PMN.270) (PDF)
- Pimavanserin (Nuplazid) (CP.PMN.140) (PDF)
- Pirfenidone (Esbriet) (CP.PHAR.286) (PDF)
- Pirtobrutinib (Jaypirca) (CP.PHAR.620) (PDF)
- Pitolisant (Wakix) (CP.PMN.221) (PDF)
- Plasminogen, Human-tvmh (Ryplazim) (CP.PHAR.513) (PDF)
- Plecanatide (Trulance) (CP.PMN.87) (PDF)
- Plerixafor (Mozobil) (CP.PHAR.323) (PDF)
- Polatuzumab Vedotin-piiq (Polivy) (CP.PHAR.433) (PDF)
- Pomalidomide (Pomalyst) (CP.PHAR.116) (PDF)
- Ponatinib (Iclusig) (CP.PHAR.112) (PDF)
- Ponesimod (Ponvory) (CP.PHAR.537) (PDF)
- Potassium Chloride for Oral Solution (Klor-Con Powder) (PDF)
- Pozelimab-bbfg (Veopoz) (CP.PHAR.626) (PDF)
- Pralatrexate (Folotyn) (CP.PHAR.313) (PDF)
- Pramlintide (Symlin) (CP.PMN.129) (PDF)
- Prasterone (Intrarosa) (CP.PMN.99) (PDF)
- Pregabalin (Lyrica, Lyrica CR) (CP.PMN.33) (PDF)
- Pretomanid (CP.PMN.222) (PDF)
- Progesterone (Crinone, Endometrin) (CP.PMN.243) (PDF)
- Propranolol HCl Oral Solution (Hemangeol) (CP.PCH.51) (PDF)
- Protein C Concentrate, Human (Ceprotin) (CP.PHAR.330) (PDF)
- Prucalopride (Motegrity) (HIM.PA.159) (PDF)
- Pyrimethamine (Daraprim) (CP.PMN.44) (PDF)
- Quantity Limit Override and Dose Optimization (CP.PMN.59) (PDF)
- Quetiapine Extended-Release (Seroquel XR) (CP.PMN.64) (PDF)
- Quinine Sulfate (Qualaquin) (PDF)
- Quizartinib (Vanflyta) (CP.PHAR.646) (PDF)
- Ramucirumab (Cyramza) (CP.PHAR.119) (PDF)
- Ranibizumab (Byooviz, Cimerli, Lucentis, Susvimo) (CP.PHAR.186) (PDF)
- Rasagiline (Azilect) (HIM.PA.89) (PDF)
- Ravulizumab-cwvz (Ultomiris) (CP.PHAR.415) (PDF)
- Regorafenib (Stivarga) (CP.PHAR.107) (PDF)
- Relugolix (Orgovyx), Relugolix/Estradiol/Norethinedrone (Myfembree) (CP.PHAR.529) (PDF)
- Remestemcel-L (Ryoncil) (CP.PHAR.474) (PDF)
- Repository Corticotropin Injection (H.P. Acthar Gel, Purified Cortrophin Gel) (HIM.PA.168) (PDF)
- Repotrectinib (Augtyro) (CP.PHAR.667) (PDF)
- Reslizumab (Cinqair) (CP.PHAR.223) (PDF)
- Resmetirom (Rezdiffra) (CP.PHAR.647) (PDF)
- Respiratory syncytial virus vaccine (Abrysvo) (CP.PHAR.658) (PDF)
- Respiratory syncytial virus vaccine (Abrysvo) (CP.PHAR.658) (PDF)
- Retifanlimab-dlwr (Zynyz) (CP.PHAR.629) (PDF)
- Revumenib (Revuforj) (CP.PHAR.707) (PDF)
- Ribavirin (CP.PHAR.141) (PDF)
- Ribociclib (Kisqali), Ribociclib/Letrozole (Kisqali Femara) (CP.PHAR.334) (PDF)
- Rifabutin (Mycobutin) (CP.PMN.223) (PDF)
- Rifamycin (Aemcolo) (CP.PMN.196) (PDF)
- Rifaximin (Xifaxan) (CP.PMN.47) (PDF)
- Rilonacept (Arcalyst) (CP.PHAR.266) (PDF)
- RimabotulinumtoxinB (Myobloc) (CP.PHAR.233) (PDF)
- Rimegepant (Nurtec ODT) (CP.PHAR.490) (PDF)
- Riociguat (Adempas) (CP.PHAR.195) (PDF)
- Ripretinib (Qinlock) (CP.PHAR.502) (PDF)
- Risdiplam (Evrysdi) (CP.PHAR.477) (PDF)
- Risedronate (Actonel, Atelvia) (PDF)
- Risperidone Long-Acting Injection (Perseris, Risperdal Consta, Risvan, Rykindo, Uzedy) (CP.PHAR.293) (PDF)
- Rituximab (Rituxan), Rituximab-arrx (Riabni), Rituximab-pvvr (Ruxience), Rituximab-abbs (Truxima), Rituximab-Hyaluronidase (Rituxan Hycela) (CP.PHAR.260) (PDF)
- Roflumilast (Daliresp, Zoryve) (CP.PMN.46) (PDF)
- Rolapitant (Varubi) (CP.PMN.102) (PDF)
- Romidepsin (Istodax) (CP.PHAR.314) (PDF)
- Romiplostim (Nplate) (CP.PHAR.179) (PDF)
- Romosozumab-aqqg (Evenity) (CP.PHAR.428) (PDF)
- Ropeginterferon Alfa-2b-njft (BESREMi) (CP.PHAR.570) (PDF)
- Rozanolixizumab-noli (Rystiggo) (CP.PHAR.648) (PDF)
- Rucaparib (Rubraca) (CP.PHAR.350) (PDF)
- Rufinamide (Banzel) (CP.PMN.157) (PDF)
- Ruxolitinib (Jakafi, Opzelura) (CP.PHAR.98) (PDF)
- Sacituzumab Govitecan-hziy (Trodelvy) (CP.PHAR.475) (PDF)
- Sacubitril/Valsartan (Entresto) (CP.PMN.67) (PDF)
- Sacubitril/Valsartan (Entresto) (CP.PCH.52) (PDF)
- Safinamide (Xadago) (CP.PMN.113) (PDF)
- Sapropterin Dihydrochloride (Kuvan) (CP.PHAR.43) (PDF)
- Sarecycline (Seysara) (CP.PMN.189) (PDF)
- Sargramostim (Leukine) (CP.PHAR.295) (PDF)
- Satralizumab-mwge (Enspryng) (CP.PHAR.463) (PDF)
- Sebelipase Alfa (Kanuma) (CP.PHAR.159) (PDF)
- Secnidazole (Solosec) (CP.PMN.103) (PDF)
- Seladelpar (Livdelzi) (CP.PHAR.698) (PDF)
- Selexipag (Uptravi) (CP.PHAR.196) (PDF)
- Selinexor (Xpovio) (CP.PHAR.431) (PDF)
- Selpercatinib (Retevmo) (CP.PHAR.478) (PDF)
- Selumetinib (Koselugo) (CP.PHAR.464) (PDF)
- Semaglutide (Wegovy) (CP.PMN.295) (PDF)
- Setmelanotide (Imcivree) (CP.PHAR.491) (PDF)
- Short Ragweed Pollen Allergen Extract (Ragwitek) (CP.PMN.83) (PDF)
- Sildenafil (Revatio, Liqrev) (CP.PHAR.197) (PDF)
- Sildenafil for ED (Viagra) (CP.PCH.07) (PDF)
- Siltuximab (Sylvant) (CP.PHAR.329) (PDF)
- Siponimod (Mayzent) (CP.PHAR.427) (PDF)
- Sirolimus Protein-Bound Particles (Fyarro), Topical Gel (CP.PHAR.574) (Hyftor) (PDF)
- Sodium Oxybate (Xyrem, Lumryz) and Calcium, Magnesium, Potassium, and Sodium Oxybate (Xywav) (CP.PMN.42) (PDF)
- Sodium Phenylbutyrate (Buphenyl, Pheburane, Olpruva) (CP.PHAR.208) (PDF)
- Sodium Phenylbutyrate/Taurursodiol (Relyvrio) (CP.PHAR.584) (PDF)
- Sodium Thiosulfate (Pedmark) (CP.PHAR.610) (PDF)
- Sodium Zirconium Cyclosilicate (Lokelma) (CP.PMN.163) (PDF)
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (HIM.PA.91) (PDF)
- Sofosbuvir (Sovaldi) (HIM.PA.SP2) (PDF)
- Sofosbuvir/Velpatasvir (Epclusa) (HIM.PA.SP1) (PDF)
- Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (HIM.PA.SP63) (PDF)
- Solriamfetol (Sunosi) (CP.PMN.209) (PDF)
- Sonidegib (Odomzo) (CP.PHAR.272) (PDF)
- Sorafenib (Nexavar) (CP.PHAR.69) (PDF)
- Sotatercept (Winrevair) (CP.PHAR.657) (PDF)
- Sotorasib (Lumakras) (CP.PHAR.549) (PDF)
- Sparsentan (Filspari) (CP.PHAR.631) (PDF)
- Spesolimab-sbzo (Spevigo) (CP.PHAR.606) (PDF)
- Spinosad (Natroba) (HIM.PA.134) (PDF)
- Step Therapy (HIM.PA.109) (PDF)
- Stiripentol (Diacomit) (CP.PMN.184) (PDF)
- Sunitinib (Sutent) (CP.PHAR.73) (PDF)
- Sutimlimab-jome (Enjaymo) (CP.PHAR.503) (PDF)
- Suvorexant (Belsomra) (CP.PMN.109) (PDF)
- Suzetrigine (Journavx) (CP.PMN.301) (PDF)
- Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract (Oralair) (CP.PMN.85) (PDF)
- Tadalafil (Adcirca, Alyq, Tadliq) (CP.PHAR.198) (PDF)
- Tadalafil BPH - ED (Cialis, Chewtadzy) (CP.PMN.132) (PDF)
- Tafamidis (Vyndaqel, Vyndamax) (CP.PHAR.432) (PDF)
- Tafasitamab-cxix (Monjuvi) (CP.PHAR.508) (PDF)
- Talazoparib (Talzenna) (CP.PHAR.409) (PDF)
- Taliglucerase Alfa (Elelyso) (CP.PHAR.157) (PDF)
- Talimogene laherepvec (Imlygic) (CP.PHAR.542) (PDF)
- Talquetamab-tgvs (Talvey) (CP.PHAR.649) (PDF)
- Tapinarof (Vtama) (CP.PMN.283) (PDF)
- Tarlatamab-dlle (Imdelltra) (CP.PHAR.685) (PDF)
- Tasimelteon (Hetlioz, Hetlioz LQ) (CP.PMN.104) (PDF)
- Tavaborole (Kerydin) (CP.PMN.105) (PDF)
- Tazarotene (Arazlo, Fabior, Tazorac) (CP.PMN.244) (PDF)
- Tazemetostat (Tazverik) (CP.PHAR.452) (PDF)
- Tebentafusp-tebn (Kimmtrak) (CP.PHAR.575) (PDF)
- Teclistamab-cqyv (Tecvayli) (CP.PHAR.611) (PDF)
- Tedizolid (Sivextro) (CP.PMN.62) (PDF)
- Teduglutide (Gattex) (CP.PHAR.114) (PDF)
- Telotristat Ethyl (Xermelo) (CP.PHAR.337) (PDF)
- Temozolomide (Temodar) (CP.PHAR.77) (PDF)
- Temsirolimus (Torisel) (CP.PHAR.324) (PDF)
- Tenapanor (Ibsrela, Xphozah) (CP.PMN.224) (PDF)
- Tenofovir Alafenamide Fumarate (Vemlidy) (CP.PMN.268) (PDF)
- Teplizumab-mzwv (Tzield) (CP.PHAR.492) (PDF)
- Tepotinib (Tepmetko) (CP.PHAR.530) (PDF)
- Teprotumumab (Tepezza) (CP.PHAR.465) (PDF)
- Teriflunomide (Aubagio) (CP.PCH.40) (PDF)
- Teriparatide (Forteo, Bonsity) (CP.PHAR.188) (PDF)
- Tesamorelin (Egrifta SV) (CP.PHAR.109) (PDF)
- Testosterone (Androderm) (HIM.PA.87) (PDF)
- Testosterone (Testopel, Jatenzo, Kyzatrex, Tlando) (CP.PHAR.354) (PDF)
- Tetrabenazine (Xenazine) (CP.PHAR.92) (PDF)
- Tezacaftor/Ivacaftor; Ivacaftor (Symdeko) (CP.PHAR.377) (PDF)
- Tezepelumab-ekko (Tezspire) (CP.PHAR.576) (PDF)
- Thalidomide (Thalomid) (CP.PHAR.78) (PDF)
- Thioguanine (Tabloid) (CP.PHAR.437) (PDF)
- Thyrotropin Alfa (Thyrogen) (CP.PHAR.95) (PDF)
- Timothy Grass Pollen Allergen Extract (Grastek) (CP.PMN.84) (PDF)
- Tiopronin Delayed-Release (Thiola EC) (CP.PHAR.725) (PDF)
- Tisagenlecleucel (Kymriah) (CP.PHAR.361) (PDF)
- Tislelizumab-jsgr (Tevimbra) (CP.PHAR.687) (PDF)
- Tisotumab Vedotin-tftv (Tivdak) (CP.PHAR.561) (PDF)
- Tivozanib (Fotivda) (CP.PHAR.538) (PDF)
- Tobramycin (Bethkis, Kitabis Pak, TOBI, TOBI Podhaler) (CP.PHAR.211) (PDF)
- Tofersen (Qalsody) (CP.PHAR.591) (PDF)
- Tolvaptan (Jynarque, Samsca) (CP.PHAR.27) (PDF)
- Topical Acne Treatment (HIM.PA.71) (PDF)
- Topical Immunomodulators (CP.PMN.107) (PDF)
- Topiramate Extended-Release (Qudexy XR, Trokendi XR) (CP.PMN.281) (PDF)
- Topotecan (Hycamtin) (CP.PHAR.64) (PDF)
- Toripalimab-tpzi (Loqtorzi) (CP.PHAR.668) (PDF)
- Tovorafenib (Ojemda) (CP.PHAR.686) (PDF)
- Trabectedin (Yondelis) (CP.PHAR.204) (PDF)
- Tralokinumab-ldrm (Adbry) (CP.PHAR.577) (PDF)
- Trametinib (Mekinist) (CP.PHAR.240) (PDF)
- Trastuzumab/Biosimilars, Trastuzumab-Hyaluronidase (CP.PHAR.228) (PDF)
- Travoprost Implant (iDose TR) (CP.PHAR.672) (PDF)
- Tremelimumab-actl (Imjudo) (CP.PHAR.612) (PDF)
- Treprostinil (Orenitram, Remodulin, Tyvaso, Tyvaso DPI) (CP.PHAR.199) (PDF)
- Triamcinolone ER Injection (Zilretta) (CP.PHAR.371) (PDF)
- Triclabendazole (Egaten) (CP.PMN.207) (PDF)
- Trientine (Cuvrior, Syprine) (CP.PHAR.438) (PDF)
- Trifarotene (Aklief) (CP.PMN.225) (PDF)
- Trifluridine/Tipiracil (Lonsurf) (CP.PHAR.383) (PDF)
- Triheptanoin (Dojolvi) (CP.PHAR.509) (PDF)
- Triptorelin Pamoate (Trelstar, Triptodur) (CP.PHAR.175) (PDF)
- Tirzepatide (Zepbound) (CP.PMN.298) (PDF) Effective Date: 3/1/2025
- Trofinetide (Daybue) (CP.PHAR.600) (PDF)
- Tucatinib (Tukysa) (CP.PHAR.497) (PDF)
- Ublituximab-xiiy (Briumvi) (CP.PHAR.621) (PDF)
- Ulcer Therapy Products (CP.PMN.277) (PDF)
- Uridine Triacetate (Vistogard) (HIM.PA.SP55) (PDF)
- Vadadustat (Vafseo) (CP.PHAR.677) (PDF)
- Valbenazine (Ingrezza, Ingrezza Sprinkle) (CP.PCH.48) (PDF)
- Valganciclovir (Valcyte) (CP.PCH.06) (PDF)
- Valoctocogene Roxaparvovec-rvox (Roctavian) (CP.PHAR.466) (PDF)
- Valrubicin (Valstar) (CP.PHAR.439) (PDF)
- Vamorolone (Agamree) (CP.PHAR.659) (PDF)
- Vandetanib (Caprelsa) (CP.PHAR.80) (PDF)
- Varenicline (Tyrvaya) (CP.PMN.273) (PDF)
- Velaglucerase Alfa (VPRIV) (CP.PHAR.163) (PDF)
- Velmanase Alfa-tycv (Lamzede) (CP.PHAR.601) (PDF)
- Vemurafenib (Zelboraf) (CP.PHAR.91) (PDF)
- Venetoclax (Venclexta) (CP.PHAR.129) (PDF)
- Verteporfin (Visudyne) (CP.PHAR.187) (PDF)
- Vestronidase Alfa-vjbk (Mepsevii) (CP.PHAR.374) (PDF)
- Vigabatrin (Sabril, Vigafyde) (CP.PHAR.169) (PDF)
- Viloxazine (Qelbree) (CP.PMN.264) (PDF)
- Viltolarsen (Viltepso) (CP.PHAR.484) (PDF)
- Vimseltinib (Romvimza) (CP.PHAR.726) (PDF)
- Vismodegib (Erivedge) (CP.PHAR.273) (PDF)
- Voclosporin (Lupkynis) (CP.PHAR.504) (PDF)
- Vorapaxar (Zontivity) (HIM.PA.146) (PDF)
- Vorasidenib (Voranigo) (CP.PHAR.699) (PDF)
- Voretigene Neparvovec-rzyl (Luxturna) (CP.PHAR.372) (PDF)
- Vorinostat (Zolinza) (CP.PHAR.83) (PDF)
- Vortioxetine (Trintellix) (CP.PMN.65) (PDF)
- Vosoritide (Voxzogo) (CP.PHAR.525) (PDF)
- Voxelotor (Oxbryta) (CP.PHAR.451) (PDF)
- Vutrisiran (Amvuttra) (CP.PHAR.550) (PDF)
- Zanidatamab-hrii (Ziihera) (CP.PHAR.709) (PDF)
- Zavegepant (Zavzpret) (CP.PHAR.630) (PDF)
- Zenocutuzumab-zbco (Bizengri) (CP.PHAR.713) (PDF) Effective Date: 3/1/2025
- Zilucoplan (Zilbrysq) (CP.PHAR.616) (PDF)
- Ziv-Aflibercept (Zaltrap) (CP.PHAR.325) (PDF)
- Zoledronic Acid (Reclast) (CP.PHAR.59) (PDF)
- Zuranolone (Zurzuvae) (CP.PHAR.650) (PDF)
- Zolbetuximab-clzb (Vyloy) (CP.PHAR.705) (PDF)